Skip to main content

#156556

Anti-CD43 [W3/13]

Cat. #156556

Anti-CD43 [W3/13]

Cat. #: 156556

Unit size: 100 ug

Availability: 10-12 weeks

Target: CD43 glycoprotein

Class: Monoclonal

Application: FACS ; IHC

Reactivity: Rat

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Institute: Medical Research Council; University of Oxford

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-CD43 [W3/13]
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Reactivity: Rat
  • Host: Mouse
  • Application: FACS ; IHC
  • Description: The antibody is directed against membrane molecules found on rat thymocytes, T-lymphocytes, bone marrow neutrophils, brain, and also on plasma and myeloma cells. The W3/13 antigen has a molecular weight of 95kDa.
  • Immunogen: Rat thymocyte membrane
  • Myeloma used: NS1/1
  • Recommended controls: IgG1

Target Details

  • Target: CD43 glycoprotein
  • Target background: The antibody is directed against membrane molecules found on rat thymocytes, T-lymphocytes, bone marrow neutrophils, brain, and also on plasma and myeloma cells. The W3/13 antigen has a molecular weight of 95kDa.

Applications

  • Application: FACS ; IHC

Handling

  • Format: Liquid
  • Unit size: 100 ug
  • Shipping conditions: Dry ice

References

  • Williams et al. 1977. Cell. 12(3):663-73. PMID: 303545.

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.